Acorda Therapeutics (ACOR) Reports Q3 EPS of 28c
Get Alerts ACOR Hot Sheet
Price: $13.50 +8.87%
EPS Growth %: -139.7%
Financial Fact:
Loss before taxes: -10.01M
Today's EPS Names:
BFRI, HCTI, IMPM, More
EPS Growth %: -139.7%
Financial Fact:
Loss before taxes: -10.01M
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.28, may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $106 million versus the consensus estimate of $94.7 million.
It raised full year 2014 guidance for AMPYRA net revenue from $328-$335 million to $345-$350 million
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Lantern Pharma (LTRN) Tops Q4 EPS by 1c
- Motus GI Holdings (MOTS) Tops Q4 EPS by 130c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!